RxDoctor Payments DataLook up a doctor →

Joseph Ojile, MD

Pulmonary Disease · Saint Louis, MONPI 1003895236

Payments from drug & device makers

$2,082,215in general payments, 2019–2025

Across 1,190 payments — averaging $1749.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$989K
  • Takeda Pharmaceuticals U.S.A., Inc.$249K
  • Fisher & Paykel Healthcare Limited$216K
  • Jazz Pharmaceuticals Inc.$145K
  • GSK$101K
  • GE HealthCare$65K
  • plus $317K from 42 others
$382,339in research payments, 2019–2025

Across 8 payments — averaging $47,792 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Somnomed Inc.$194K
  • Philips North America LLC$189K

What the payments were for

  • Consulting fees$294,53355%
  • Speaking & faculty fees$208,59039%
  • Travel & lodging$15,6703%
  • Food & beverage$18,6893%
  • Education$3700%
  • Gifts$1410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,082,215 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$146,115
Medicare patients
903
Services billed
1,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter638$476,112
Prolastin CAlpha-1-Proteinase Inhibitor13$146,121
Breztri AerosphereBudesonide/Glycopyr/Formoterol135$112,003
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$90,096
Breo ElliptaFluticasone/Vilanterol156$76,197
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr78$39,380
Combivent RespimatIpratropium/Albuterol Sulfate31$24,552
Ambrisentan13$20,764
Arnuity ElliptaFluticasone Furoate63$18,115
NuvigilArmodafinil13$13,986
Albuterol Sulfate HfaAlbuterol Sulfate488$12,410
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$10,796
SymbicortBudesonide/Formoterol Fumarate31$10,430
Spiriva HandihalerTiotropium Bromide13$9,999
Spiriva RespimatTiotropium Bromide14$9,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$101,351$609,805935 claims
Grifols USA, LLCProlastin C$423$146,12113 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$36,013$125,662179 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$248,988$90,09617 claims
Boehringer IngelheimCombivent Respimat, Spiriva Respimat$5,503$33,62045 claims
PfizerEliquis$14$5,02715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →